TABLE 5.

Antiviral activity of HIV-1 strains mutated at glycosylation sites in gp120

CompoundEC50 (μM) for wild typeAntiviral activity (fold resistance) for virus isolatea:
123456789101112131415161718
HHA0.0066.3191.91755280.8838315133110397567262919490
GNA0.0105.28.31.91040270.331336.13944117727899926581
CA0.02410118.16.727131.94245323932458558140233133
LOA5.83.85.05.51.3323310102158804316109228246
CV-N0.0031.57.40.684.27.96.80.343371.35750832.96.35.12911
  • a 1, PRMA-8-1; 2, PRMA-30-1; 3, PRMA-8-2; 4, PRMA-30-2; 5, PRMA-30-3; 6, PRMA-30-4; 7, UDA-20; 8, UDA-25-1; 9, UDA-50-1; 10, UDA-15-2; 11, UDA-50-2; 12, UDA-100-2; 13, UDA-200-2; 14, GNA-2.1; 15, HHA-2.2; 16, HHA-500CS; 17, HHA-500SN; 18, GNA-500CS.